HO
HOFBF.US Hofseth BioCare ASA
- Market cap
- USD 59.9M
- P/E
- -
- P/B
- 647.46x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HOFBF.US undervalued?
Graham numberThe Graham number of Hofseth BioCare ASA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hofseth BioCare ASA fundamental analysis
No fundamental analysis for Hofseth BioCare ASA yet.
Hofseth BioCare ASA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hofseth BioCare ASA
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Turkey, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a fish oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are calcium collagen complexes that support joint and bone health; CollaGo; and …
Full company profileHofseth BioCare ASA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hofseth BioCare ASA annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 20.2M | 118M | 60.7M | 67.8M | 69.3M | 87.6M | 120M | 195M | 257M | 254M | 260M |
| Gross Profit | -81.2M | 63.5M | 12.4M | 8.21M | 29.7M | 23.1M | 28.5M | 44.2M | 87.9M | -32.5M | 51.9M |
| Operating Income | -145M | -11.2M | -77.7M | -79.6M | -92.0M | -119M | -129M | -103M | -113M | -113M | -69.7M |
| EBITDA | -119M | 8.54M | -58.5M | -53.2M | -66.1M | -87.7M | -97.2M | -62.7M | -67.9M | -73.2M | -31.5M |
| Net Income | -147M | -16.5M | -84.8M | -89.2M | -102M | -126M | -137M | -107M | -123M | -135M | -97.2M |
| EPS | -1.01 | -0.07 | -0.33 | -0.29 | -0.31 | -0.35 | -0.37 | -0.27 | -0.30 | -0.33 | -0.23 |
| Balance Sheet | |||||||||||
| Total Assets | 159M | 184M | 188M | 293M | 459M | 416M | 411M | 390M | 341M | 394M | 360M |
| Total Liabilities | 106M | 147M | 102M | 175M | 195M | 276M | 263M | 349M | 280M | 470M | 362M |
| Shareholders' Equity | 54.2M | 37.7M | 86.7M | 118M | 264M | 141M | 149M | 41.8M | 62.0M | -74.8M | -1.78M |
| Cash & Short-term Investments | 15.2M | 40.7M | 48.6M | 93.2M | 171M | 47.2M | 29.9M | 23.9M | 25.6M | 67.0M | 33.6M |
| Total Debt | 74.4M | 81.4M | 58.3M | 135M | 101M | 139M | 104M | 281M | 171M | 301M | 282M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -67.2M | -25.5M | -28.6M | -31.1M | -61.6M | -61.8M | -45.2M | 2.76M | -9.82M | -38.4M | -105M |
| Capital Expenditure | 42.6M | 13.8M | 9.84M | 28.8M | 54.5M | 37.8M | 17.8M | 14.1M | 4.07M | 25.3M | 19.8M |
| Free Cash Flow | -110M | -39.3M | -38.5M | -59.9M | -116M | -99.5M | -62.9M | -11.3M | -13.9M | -63.7M | -125M |
| Ratios | |||||||||||
| ROE | -271.9% | -43.6% | -97.8% | -75.3% | -38.6% | -89.7% | -92.4% | -255.1% | -199.1% | - | - |
| ROA | -92.5% | -8.9% | -45.1% | -30.4% | -22.2% | -30.4% | -33.4% | -27.3% | -36.1% | -34.2% | -27.0% |
| Net Profit Margin | -729.8% | -13.9% | -139.6% | -131.6% | -147.4% | -144.3% | -114.1% | -54.7% | -47.9% | -53.0% | -37.4% |
| Debt to Equity | 1.37x | 2.16x | 0.67x | 1.14x | 0.38x | 0.99x | 0.70x | 6.71x | 2.76x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hofseth BioCare ASA dividends
Hofseth BioCare ASA has not paid dividends in the last 9 fiscal years.
Who owns Hofseth BioCare ASA
- Insiders 39.23%
- Institutions 12.97%
- Public & others 47.80%
- Shares outstanding 506M
- Free float 77.7M
Hofseth BioCare ASA company profile
- Company name
- Hofseth BioCare ASA
- Ticker
- HOFBF.US
- Exchange
- USA Stocks
- Sector
- Consumer Defensive
- Industry
- Biotechnology
- Employees
- 78
- Fiscal year end
- December
- Address
- Keiser Wilhelms gate 24, Ålesund, Norway, 6003
- Phone
- 47 73 10 22 00
- Website
- hofsethbiocare.com
About Hofseth BioCare ASA
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Turkey, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a fish oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are calcium collagen complexes that support joint and bone health; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was founded in 2000 and is headquartered in Ålesund, Norway.
Hofseth BioCare ASA management
9- Mr. Jon Olav OdegardChief Executive Officer
- Dr. Bomi Framroze Ph.D.Chief Scientific Officer · born 1961
- Mr. James BergerChief Commercial Officer
- Ms. Angelika FlorvaagChief Quality Officer
- Dr. Crawford Linden Alexander Currie M.B.A., M.D.Head of Medical R&D and Director
- Mr. Leif Arne GiskeChief Financial Officer
- Mr. Magnus HavnenHead of Supply Chain
- Mr. Tom JamesHead of Manufacturing
- Mr. Paul BruhnHead of New Business Development & Director